Ireland
--:--IST
Recruiting Observational

Clinical Data Collection of Patients Treated With High Intensity Focused Ultrasound (HIFU) by the Focal One for Their Prostate Cancer.

NCT07645872 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2023-02-01
Last updated
2026-06-12

Condition(s) studied

Prostate Cancer

Study summary

The aim of the registry is to gather real-life data to evaluate the clinical performance and safety of medical devices in patients who have been treated with HIFU thank to the Focal One device for their prostate cancer.

Eligibility

Sex
MALE
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Being treated for prostate cancer with the Focal One device * Patient does not object and consent\* to the collection of clinical data in the registry Exclusion Criteria: * Patient deprived of liberty following a judicial or administrative decision * Patient under guardianship or curatorship \* if applicable according to local regulation

Primary outcome measure(s)

  • To monitor the safety of HIFU treatment with the Focal One in patients treated for prostate cancer. — From HIFU treatment up to 5 years post-HIFU
    Safety will be assessed by collecting adverse events related to HIFU treatment.

Trial sites (5)

FacilityCityRegionStatus
Hôpital privé Aix en provence Aix-en-Provence France Recruiting
Clinique Saint vincent Besançon France Recruiting
Hôpital Civil Colmar Colmar France Recruiting
Hôpital Edouard Heriot Lyon France Recruiting
Clinique Nantes Atlantis Nantes France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07645872 on ClinicalTrials.gov ↗ ← All trials in France